SAN FRANCISCO, Oct. 29 – Xanthon will partner with Duke University and University of North Carolina at Chapel Hill scientists in a two-year oligonucleotide array project that received funding from the North Carolina Biotechnology Center, the company announced Monday.
The project is called “Fabrication and Interrogation of Ultradense Oligonucleotide Arrays.” Xanthon will commercialize resulting technology, the company said.
Grant amount and details of the agreement between Xanthon and the universities were not disclosed.
The project, according to the company, is aimed at developing fabrication methods, attachment chemistry, and electrochemical detection schema for high-density electrode arrays on the order of up to 10,000,000 electrodes per square centimeter.
Xanthon, based in Research Triangle Park, NC, is developing a series of analytical platforms based on its proprietary electrochemical technology that it says can make biomolecule detection and information processing more efficient.
Xanthon's first product, the Xpression high-throughput gene-expression analysis system, will be launched to pharmaceutical companies early next year, the company said.
Last week, the company won a patent in Australia that covers a method of directly detecting biomolecules through a “transition-metal-mediated, catalytic, oxidation-reduction reaction,” according to the company.